Private Banking
|
Professional Solutions
|
Investment Management
|
Investment Banking
|
About us
EN
Contact
Login
Van Lanschot Kempen Logo
Solutions
Sectors
Careers
Van Lanschot Kempen Logo
Login
Home
Investment Banking
Corporate Finance
Transactions
March 2024
Joint Global Coordinator & Joint Bookrunner
SEK 2,097 million
Accelerated Bookbuild Offering
February 2024
Sole Financial Adviser
Undisclosed
Sale to Visma
February 2024
Co-Manager
USD 350 million
US Offering
January 2024
Financial Adviser
€170 million
Sale of Jyseleca business to Alfasigma
December 2023
Sole Financial Adviser
€90 million
Venture debt financing
December 2023
Sole Bookrunner
€51.8 million
Sale of shares
November 2023
Financial Adviser
€135 million
U.S. Private Placement
December 2023
Joint Global Coordinator and Joint Bookrunner
€300 million
Accelerated Bookbuild Offering
November 2023
Joint Global Coordinator & Joint Bookrunner
€126 million
Accelerated Bookbuild Offering
October 2023
Joint Global Coordinator & Joint Bookrunner
SEK 59.3 million
Directed Share Issue
October 2023
Joint Global Coordinator & Joint Lead Bookrunner
NOK 505 million
Accelerated Bookbuild Offering
October 2023
Sole Financial Adviser
€260 million
Green Loan
October 2023
Sole Financial Adviser
SEK 120 million
Structured Equity with Warrants
October 2023
Financial Adviser
Undisclosed
Acquisition of Novec GmbH
October 2023
Joint Bookrunner
€167 million
Accelerated Bookbuild Offering
September 2023
Sole Financial Adviser
€625 million
Green Loan
September 2023
Adviser
€500 million
Proposed investment in Stedin Groep
August 2023
Lead manager
USD 173 million
Capital Increase
July 2023
Manager
USD 1.3 billion
Capital Increase
July 2023
Sole Financial Adviser
€65 million
Secured Term Loan Extension
June 2023
Joint Venture
Undisclosed
Sole Financial Adviser
June 2023
Joint Bookrunner
SEK 500 million
Capital increase
June 2023
Financial Adviser
USD 182 million
Secondary sell-down
May 2023
Joint Global Coordinator & Joint Bookrunner
€25.0 million
Accelerated Bookbuild Offering
May 2023
Sole Financial Adviser
Undisclosed
Joint Venture
April 2023
Financial Adviser
>USD 100 million
Series B funding round
April 2023
Joint Global Coordinator & Joint Bookrunner
€ 15.8 million
Accelerated Bookbuild Offering
April 2023
Lead Manager
DKK 1.5 billion
Accelerated Bookbuild Offering
March 2023
Sole Financial Adviser
€ 14 million
Series B funding round
March 2023
Financial Advisor, Capital Markets Advisor & Placement Agent
USD 220m
PIPE USD 91 million
Feb 2023
Lead Manager
USD 250 million
US Public Offering
Jan 2023
Sole Financial Adviser
circa € 500 million
Structured Equity and Senior Debt Financing
Dec 2022
Sole Financial Adviser
€ 12.0 million
Convertible Note Issuance
Dec 2022
Joint Global Coordinator & Joint Bookrunner
SEK 416 million
PIPE
Dec 2022
Sole Financial Adviser
€50 million
Term Loan Extension
Dec 2022
Joint Global Coordinator & Joint Bookrunner
SEK 80 million
Directed Share Issue via PIPE
Dec 2022
Sole Financial Adviser
SEK 191 million
Acquisition of TXP Pharma
Dec 2022
Joint Bookrunner
SEK 200 million
Accelerated Bookbuild Offering
Dec 2022
Joint Bookrunner
SEK 148 million
Guaranteed Rights Issue
Dec 2022
Joint Global Coordinator & Joint Bookrunner
SEK 1,642 million
Accelerated Bookbuild Offering
Dec 2022
Sole Block Placing Agent
1.3 million shares
Block Trade in Molecular Partner Shares
Nov 2022
Sole Financial Adviser
€ 35.0 million
Secures a credit facility from the European Investment Bank
Nov 2022
Sole Financial Adviser
€ 15.0 million
Secures venture debt funding from the European Investment Bank
Oct 2022
Joint Global Coordinator & Joint Bookrunner
SEK 170 million
Accelerated Bookbuild Offering
Oct 2022
Joint Global Coordinator & Joint Bookrunner
€ 300 million
Accelerated Bookbuild Offering
Oct 2022
Co-Lead Manager
DKK 786 million
Accelerated Bookbuild Offering
Sep 2022
Sole Financial Adviser
Development Financing for The Ensemble
Sep 2022
Joint Bookrunner
€ 61.5 million
Sale of existing shares via club deal
Sep 2022
Sole Financial Broker
€ 4,332 million
The acquisition of all Boskalis issued and outstanding shares
Sep 2022
Sole Financial Adviser
€ 200 million
Extension of Credit Facilities
Aug 2022
Sole Financial Adviser
SEK 250 million
Convertible Bonds & Shareholder commitment
Aug 2022
Sole Financial Advisor
Sanquin Health Solutions selling its reagents branch to the Dutch Gilde Healthcare
Jul 2022
Sole Financial Adviser
€ 450 million
Sustainability Linked Unsecured Revolving Credit Facility
Jul 2022
Joint Global Coordinator
SEK 299 milion
Directed share issue via club deal
Jul 2022
Sole Financial Adviser
€ 156 million
Acquisition of Almere Centrum
Jun 2022
Sole Global Coordinator
SEK 200 million
PIPE Rights Issue
Jan 2022
Sole Financial Adviser
€ 330 million
Non-listed equity raise of European Logistics Fund
Jun 2021
Joint Global Coordinator
& Joint Bookrunner
€ 286 million
Accelerated Bookbuild Offering
Oct 2020
Joint Bookrunner
€ 460 million
Capital increase
Jan 2020
Joint Financial Adviser
€ 610 million
Public takeover of Finnish Hoivatilat
Mar 2018
Sole Financial Adviser
Undisclosed
Sale of Residential Portfolio
Jan 2018
Co-lead Manager
€ 193 million
Accelerated Bookbuild Offering
Dec 2015
Financial Adviser
Sale of the European Veterinary Business to Fidelio
All transactions
See all transactions made throughout the years.
All transactions in 2024
All transactions in 2023
All transactions in 2022
All transactions in 2021
All transactions in 2020
All transactions in 2019
All transactions in 2018
All transactions in 2017
All transactions in 2016
All transactions in 2015
All transactions in 2014
All transactions in 2013